Rédini F - Search Results

1

Receptor activator of nuclear factor-kappaB ligand (RANKL) directly modulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells.

Mori K, Berreur M, Blanchard F, Chevalier C, Guisle-Marsollier I, Masson M, Rédini F, Heymann D. Mori K, et al. Among authors: redini f. Oncol Rep. 2007 Dec;18(6):1365-71. Oncol Rep. 2007. PMID: 17982618 Free article.

2

Osteoprotegerin: a new therapeutic agent for the treatment of bone disease.

Grimaud E, Redini F, Heymann D. Grimaud E, et al. Among authors: redini f. Drug Discov Today. 2001 Dec 1;6(23):1241-1242. doi: 10.1016/s1359-6446(01)02037-2. Drug Discov Today. 2001. PMID: 11722878 No abstract available.

3

Recent advances in TGF-beta effects on chondrocyte metabolism. Potential therapeutic roles of TGF-beta in cartilage disorders.

Grimaud E, Heymann D, Rédini F. Grimaud E, et al. Among authors: redini f. Cytokine Growth Factor Rev. 2002 Jun;13(3):241-57. doi: 10.1016/s1359-6101(02)00004-7. Cytokine Growth Factor Rev. 2002. PMID: 12486877 Review.

4

Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis.

Grimaud E, Soubigou L, Couillaud S, Coipeau P, Moreau A, Passuti N, Gouin F, Redini F, Heymann D. Grimaud E, et al. Among authors: redini f. Am J Pathol. 2003 Nov;163(5):2021-31. doi: 10.1016/s0002-9440(10)63560-2. Am J Pathol. 2003. PMID: 14578201 Free PMC article.

5

Bisphosphonates: new therapeutic agents for the treatment of bone tumors.

Heymann D, Ory B, Gouin F, Green JR, Rédini F. Heymann D, et al. Among authors: redini f. Trends Mol Med. 2004 Jul;10(7):337-43. doi: 10.1016/j.molmed.2004.05.007. Trends Mol Med. 2004. PMID: 15242682 Review.

6

Downregulation of osteoblast markers and induction of the glial fibrillary acidic protein by oncostatin M in osteosarcoma cells require PKCdelta and STAT3.

Chipoy C, Berreur M, Couillaud S, Pradal G, Vallette F, Colombeix C, Rédini F, Heymann D, Blanchard F. Chipoy C, et al. Among authors: redini f. J Bone Miner Res. 2004 Nov;19(11):1850-61. doi: 10.1359/JBMR.040817. Epub 2004 Aug 23. J Bone Miner Res. 2004. PMID: 15476586 Free article.

7

The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling.

Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D. Theoleyre S, et al. Among authors: redini f. Cytokine Growth Factor Rev. 2004 Dec;15(6):457-75. doi: 10.1016/j.cytogfr.2004.06.004. Cytokine Growth Factor Rev. 2004. PMID: 15561602 Review.

8

Osteolytic bone diseases: physiological analogues of bone resorption effectors as alternative therapeutic tools.

Heymann D, Fortun Y, Rédini F, Padrines M. Heymann D, et al. Among authors: redini f. Drug Discov Today. 2005 Feb 15;10(4):242-7. doi: 10.1016/S1359-6446(04)03265-9. Drug Discov Today. 2005. PMID: 15708742 Review.

9

Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice.

Ory B, Heymann MF, Kamijo A, Gouin F, Heymann D, Redini F. Ory B, et al. Among authors: redini f. Cancer. 2005 Dec 1;104(11):2522-9. doi: 10.1002/cncr.21530. Cancer. 2005. PMID: 16270320 Free article.

10

RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells.

Wittrant Y, Lamoureux F, Mori K, Riet A, Kamijo A, Heymann D, Redini F. Wittrant Y, et al. Among authors: redini f. Int J Oncol. 2006 Jan;28(1):261-9. Int J Oncol. 2006. PMID: 16328004 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

184 results

Search Page

Filters